论文部分内容阅读
我国是肝炎大国,最新统计显示,我国各类肝病患者累计达到近2亿人,每年用于诊疗的费用超过1000亿元人民币。人们谈“肝病”而色变。肝病家族里有甲肝、乙肝、丙肝、丁肝及戊肝等。一个触目惊心的数据显示着:我国目前丙肝病毒感染者约占总人口的3.2%,丙肝抗体阳性患者近4000万。丙肝发病率明显趋升,丙肝的防治以及人们对其的忽视使得它成为一个世界性难题。目前有关丙型肝炎的检测指标尚未被列入常规体检项目,使很多丙肝抗体阳性患者不能被筛选出来,这为早期发现、诊断和治疗丙型肝炎带来了困难。本期健康沙龙,我们特别邀请赵龙凤专家,就丙型肝炎的防治进行解答。
China is a major hepatitis country. The latest statistics show that all kinds of liver disease patients in our country have accumulated nearly 200 million people, and the annual cost for diagnosis and treatment has exceeded 100 billion yuan. People talk about “liver disease” and discoloration. Liver disease family has hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E and so on. A shocking data show that: China’s current hepatitis C virus infection accounts for about 3.2% of the total population, nearly 40 million patients with positive hepatitis C antibodies. The incidence of hepatitis C is obviously rising. The prevention and treatment of hepatitis C and its neglect make it a worldwide problem. At present, the detection index of hepatitis C has not been included in the routine medical examination, so many patients with positive hepatitis C can not be screened out, which makes it difficult for the early detection, diagnosis and treatment of hepatitis C. This issue of health salon, we invited specialists Zhao Longfeng, hepatitis C prevention and treatment to answer.